Comprehensive assessment of cancer missense mutation clustering in protein structures

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 40, 2015, Pages E5486-E5495

  Kamburov, Atanas ^a,b,c   Lawrence, Michael S ^c   Polak, Paz ^a,b,c   Leshchiner, Ignaty ^c   Lage, Kasper ^a,b,c   Golub, Todd R ^c   Lander, Eric S ^c   Getz, Gad ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Cancer; Cancer genetics; Interaction interfaces; Mutation clustering; Protein structures

Indexed keywords

B RAF KINASE; CULLIN; CULLIN 4B; CULLIN ASSOCIATED NEDD8 DISSOCIATED 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; CYCLIN E1; CYCLINE; DNA; F BOX WD REPEAT CONTAINING PROTEIN 7; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN RASA1; HOST CELL FACTOR C1; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; ONCOPROTEIN HRAS; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAC1 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFERASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; CELL CYCLE PROTEIN; NUF2 PROTEIN, HUMAN; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANEUPLOIDY; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CENTROMERE; CHROMOSOMAL INSTABILITY; CHROMOSOME SEGREGATION; COLORECTAL TUMOR; FRAMESHIFT MUTATION; HISTONE ACETYLATION; HUMAN; MISSENSE MUTATION; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SISTER CHROMATID; SOMATIC MUTATION; ALGORITHM; CHEMISTRY; CLUSTER ANALYSIS; ENZYME ACTIVE SITE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULAR MODEL; NEOPLASM; PROCEDURES; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN TERTIARY STRUCTURE;

ALGORITHMS; CATALYTIC DOMAIN; CELL CYCLE PROTEINS; CLUSTER ANALYSIS; DATABASES, PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; PROTEIN STRUCTURE, TERTIARY;

EID: 84943411478     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1516373112     Document Type: Article

References (83)

1. The Cancer Genome Atlas Research Network (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113-1120.
2. International Cancer Genome Consortium (2010) International network of cancer genome projects. Nature 464 (7291):993-998.
3. Lawrence MS, et al (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (7484):495-501.
4. Tamborero D, Gonzalez-Perez A, Lopez-Bigas N (2013) OncodriveCLUST: Exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29(18):2238-2244.
5. Vogelstein B, et al (2013) Cancer genome landscapes. Science 339 (6127):1546-1558.
6. Porta-Pardo E., Godzik A. (2014) e-Driver: A novel method to identify protein regions driving cancer. Bioinformatics 30(21):3109-3114.
7. Ostrem JM, Peters U, Sos M.L., Wells JA, Shokat K.M. (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503 (7477):548-551.
8. Lynch TJ, et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139.
9. Huang CH, et al (2007) The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318 (5857):1744-1748.
10. Chapman MA, et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471 (7339):467-472.
11. Barbieri CE, et al (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685-689.
12. Park YB, Chae J, Kim Y.C., Cho Y. (2011) Crystal structure of human Mre11: Understanding tumorigenic mutations. Structure 19(11):1591-1602.
13. Van Allen E.M., et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4(10):1140-1153.
14. Stehr H, et al (2011) The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. Mol Cancer 10:54.
15. Ryslik GA, et al (2014) A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. BMC Bioinformatics 15:231.
16. Wang X, et al (2012) Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol 30(2):159-164.
17. Berman HM, Kleywegt GJ, Nakamura H, Markley J.L. (2014) The Protein Data Bank archive as an open data resource. J Comput Aided Mol Des 28(10):1009-1014.
18. Lawrence MS, et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (7457):214-218.
19. Sablina AA, et al (2007) The tumor suppressor PP2AAbeta regulates the RalAGTPase. Cell 129(5):969-982.
20. Alushin GM, et al (2010) The Ndc80 kinetochore complex forms oligomeric arrays along microtubules. Nature 467 (7317):805-810.
21. Yuen KWY, Montpetit B, Hieter P. (2005) The kinetochore and cancer: What's the connection? Curr Opin Cell Biol 17(6):576-582.
22. Nabetani A, Koujin T, Tsutsumi C., Haraguchi T, Hiraoka Y. (2001) A conserved protein, Nuf2, is implicated in connecting the centromere to the spindle during chromosome segregation: A link between the kinetochore function and the spindle checkpoint. Chromosoma 110(5):322-334.
23. Hayama S, et al (2006) Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 66(21):10339-10348.
24. Kaneko N, et al (2009) siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. Biochem Biophys Res Commun 390(4):1235-1240.
25. Kobayashi Y, et al (2014) Cell division cycle-associated protein 1 overexpression is essential for the malignant potential of colorectal cancers. Int J Oncol 44(1):69-77.
26. Liu Q, Dai SJ, Li H, Dong L., Peng Y.P. (2014) Silencing of NUF2 inhibits tumor growth and induces apoptosis in human hepatocellular carcinomas. Asian Pac J Cancer Prev 15(20):8623-8629.
27. Sethi G, et al (2012) An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One 7(10):e47086.
28. Hu P, Chen X, Sun J., Bie P, Zhang L. (2015) siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep 35(1):e00170.
29. Forbes SA, et al (2011) COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39(Database issue):D945-D950.
30. Futreal PA, et al (2004) A census of human cancer genes. Nat Rev Cancer 4(3):177-183.
31. Ozturk M (1991) p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338 (8779):1356-1359.
32. Yang F, et al (2015) Protein domain-level landscape of cancer-type-specific somatic mutations. PLOS Comput Biol 11(3):e1004147.
33. Dawson JP, et al (2005) Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25(17):7734-7742.
34. Vivanco I, et al (2012) Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2(5):458-471.
35. The Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497 (7447):67-73.
36. Theurillat JPP, et al (2014) Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346 (6205):85-89.
37. Zhuang M, et al (2009) Structures of SPOP-substrate complexes: Insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell 36(1):39-50.
38. Zhong Q, et al (2009) Edgetic perturbation models of human inherited disorders. Mol Syst Biol 5:321.
39. Guo Y, et al (2013) Dissecting disease inheritance modes in a three-dimensional protein network challenges the "guilt-by-association" principle. Am J Hum Genet 93(1):78-89.
40. Mosca R, et al (2015) dSysMap: Exploring the edgetic role of disease mutations. Nat Methods 12(3):167-168.
41. Ryan CJ, et al (2013) High-resolution network biology: Connecting sequence with function. Nat Rev Genet 14(12):865-879.
42. Sahni N, et al (2015) Widespread macromolecular interaction perturbations in human genetic disorders. Cell 161(3):647-660.
43. Nishi H, et al (2013) Cancer missense mutations alter binding properties of proteins and their interaction networks. PLoS One 8(6):e66273.
44. Hao B, Oehlmann S, Sowa M.E., Harper JW, Pavletich N.P. (2007) Structure of a Fbw7-Skp1-cyclin E complex: Multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 26(1):131-143.
45. The Cancer Genome Atlas Research Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (7407):330-337.
46. Moberg KH, Bell DW, Wahrer D.C., Haber DA, Hariharan I.K. (2001) Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413 (6853):311-316.
47. Akhoondi S, et al (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67(19):9006-9012.
48. Zou Y, et al (2009) Characterization of nuclear localization signal in the N terminus of CUL4B and its essential role in cyclin E degradation and cell cycle progression. J Biol Chem 284(48):33320-33332.
49. Ghosh P, Wu M, Zhang H., Sun H. (2008) mTORC1 signaling requires proteasomal function and the involvement of CUL4-DDB1 ubiquitin E3 ligase. Cell Cycle 7(3):373-381.
50. Wang H, et al (2006) Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell 22(3):383-394.
51. Guerrero-Santoro J., et al (2008) The cullin 4B-based UV-damaged DNA-binding protein ligase binds to UV-damaged chromatin and ubiquitinates histone H2A. Cancer Res 68(13):5014-5022.
52. Lee J, Zhou P. (2010) Cullins and cancer. Genes Cancer 1(7):690-699.
53. Korzeniewski N, Hohenfellner M, Duensing S. (2012) CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. Neoplasia 14(9):799-806.
54. Salon C, et al (2007) Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: Relationships with CAND1 and cyclin E protein levels. J Pathol 213(3):303-310.
55. Murata T, et al (2010) miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 13(4):356-361.
56. Misaghi S, et al (2009) Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol 29(8):2181-2192.
57. Carbone M, et al (2013) BAP1 and cancer. Nat Rev Cancer 13(3):153-159.
58. Capotosti F, et al (2011) O-GlcNAc transferase catalyzes site-specific proteolysis of HCF-1. Cell 144(3):376-388.
59. The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (7517):202-209.
60. Cheng M, Chen Y, Xiao W., Sun R, Tian Z. (2013) NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 10(3):230-252.
61. Hanahan D, Weinberg R.A. (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
62. Min JH, et al (2002) Structure of an HIF-1α-pVHL complex: Hydroxyproline recognition in signaling. Science 296 (5574):1886-1889.
63. Takeshita D, et al (2007) Homodimeric structure and double-stranded RNA cleavage activity of the C-terminal RNase III domain of human dicer. J Mol Biol 374(1):106-120.
64. Nair SK, Burley S.K. (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2):193-205.
65. Daubner GM, Cléry A, Jayne S., Stevenin J, Allain FHT (2012) A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO J 31(1):162-174.
66. Rechsteiner MP, et al (2011) VHL gene mutations and their effects on hypoxia inducible factor HIFα: Identification of potential driver and passenger mutations. Cancer Res 71(16):5500-5511.
67. Sato Y, et al (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45(8):860-867.
68. Prior IA, Lewis PD, Mattos C. (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72(10):2457-2467.
69. Provost P, et al (2002) Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J 21(21):5864-5874.
70. Slade I, et al (2011) DICER1 syndrome: Clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 48(4):273-278.
71. Martello G, et al (2010) A MicroRNA targeting dicer for metastasis control. Cell 141(7):1195-1207.
72. Lee JO, et al (1999) Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell 99(3):323-334.
73. Burnichon N, et al (2012) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18(10):2828-2837.
74. Zack TI, et al (2013) Pan-cancer patterns of somatic copy number alteration. Nat Genet 45(10):1134-1140.
75. Zhang SJ, et al (2012) Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 119(19):4480-4485.
76. Guo J, et al (2011) Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res 71(8):2978-2987.
77. Dalton SR, Bellacosa A. (2012) DNA demethylation by TDG. Epigenomics 4(4):459-467.
78. Das J, et al (2014) Elucidating common structural features of human pathogenic variations using large-scale atomic-resolution protein networks. Hum Mutat 35(5):585-593.
79. Alber F, Förster F, Korkin D., Topf M, Sali A. (2008) Integrating diverse data for structure determination of macromolecular assemblies. Annu Rev Biochem 77:443-477.
80. Ramos AH, et al (2015) Oncotator: Cancer variant annotation tool. Hum Mutat 36(4): E2423-E2429.
81. Velankar S, et al (2013) SIFTS: Structure Integration with Function, Taxonomy and Sequences resource. Nucleic Acids Res 41(Database issue):D483-D489.
82. de Beer TAP, Berka K, Thornton JM, Laskowski RA (2014) PDBsum additions. Nucleic Acids Res 42(Database issue):D292-D296.
83. Benjamini Y, Hochberg Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. JR Stat Soc 57(1):289-300.